NMT1 and hematopoietic and lymphoid system neoplasm: NMT levels are elevated in several cancers and NMT inhibition has advanced to clinical trials for the treatment of NMT-deficient blood cancers (Selvakumar et al., 2007; Berthiaume and Beauchamp, 2018).